Management of acute severe behavioural disturbance in Australia and in the UK
Dear Sir, In a recent study, O'Connor and Corish 1 reviewed 26 protocols for the pharmacological management of acute severe behavioural distur bance (ASBD) used in Australasian psychiatric settings. They found considerable differences between the various protocols used. There are even bigger differences when the protocols are compared with prac tices in the UK, where we are based.
We were surprised to read that the maximum doses of medications for ASBD were much higher than those recommended in the UK. For instance, with olanzapine the maxi mum dose for oral medication was 30 mg compared with 20 mg in the British National Formulary (BNF). Similarly, the maximum dosage of oral lorazepam was 20 mg in 24 h, whereas the recommended maxi mum dosage for oral lorazepam is 4 mg in the BNF. However, prescribers can go above the BNF maximum, if this is clinically indicated.
Recent research showed, at least for intramuscular (IM) administered medication, that higher dosages increase the risk of side effects and do not always result in more rapid or effective sedation. 2 We were wondering whether the protocols should not be changed. Perhaps protocols should advise specifically on commencing with a relatively low starting dose, unless of course the patient has a recent history of not responding to this dose.
It is not only the dosages that are dif ferent, but also the types of medica tion recommended. Droperidol IM is mentioned in various Australasian protocols, but in the UK, it can no longer be prescribed routinely for rapid tranquillization. 3 Conversely, aripiprazole IM is not mentioned in any of the provided schemes but is currently considered as one of the saf est and most effective of the IM antip sychotics used for ASBD in Europe. 4 It is widely used in rapid tranquilliza tion protocols in the majority of men tal health trusts in the UK.
We agree with the authors that there is a lack of evidence from rand omized controlled trials for this patient group. Despite this, the avail able published evidence is more or less the same in the UK and Australia and it is striking that it has been interpreted in such different ways, both at a national and at a local level. (There are differences between local policies in the UK as well.)
The most notable difference between the two countries is that droperidol's risk of arrhythmias has resulted in a ban in the UK 3 up to this day, while a study from Australia published in 2015 found that it can be safely administered. 5 In our view, this dif ferent interpretation of empirical findings and/or lack of awareness of recent studies is something which urgently needs to be addressed. Given the nature and the amount of differ ences, it seems unlikely that the best available practice is used everywhere. Perhaps, the available evidence should be evaluated internationally and countries and/or healthcare pro viders should only make their own choices if the evidence is not clear. 
